# Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

> **NCT00906698** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 55 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992 low (20mg) dosage
- **DRUG:** BIBW 2992 medium (40mg) dosage
- **DRUG:** BIBW 2992 high (50mg) dosage
- **DRUG:** Vinorelbine per os 60 mg/m²
- **DRUG:** Vinorelbine per os 80 mg/m²
- **DRUG:** Vinorelbine i.v. 25 mg/m²

## Key facts

- **NCT ID:** NCT00906698
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906698, "Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00906698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*